Valproate-induced burning mouth syndrome in a male with fibromyalgia and bipolar spectrum disorder.

IF 0.8 Q3 MEDICINE, GENERAL & INTERNAL
Archive of clinical cases Pub Date : 2023-09-20 eCollection Date: 2023-01-01 DOI:10.22551/2023.40.1003.10257
Accursio Raia, Valerio Caruso, Clara Montalbano, Lavinia Migli, Calogero Raia, Stefano Pini
{"title":"Valproate-induced burning mouth syndrome in a male with fibromyalgia and bipolar spectrum disorder.","authors":"Accursio Raia,&nbsp;Valerio Caruso,&nbsp;Clara Montalbano,&nbsp;Lavinia Migli,&nbsp;Calogero Raia,&nbsp;Stefano Pini","doi":"10.22551/2023.40.1003.10257","DOIUrl":null,"url":null,"abstract":"<p><p>Burning mouth syndrome is a chronic painful condition characterized by a subjective intraoral pain and burning sensations in the absence of an identifiable medical, dental, or psychiatric cause. Although the underlying etiology is currently unclear, an idiopathic (or primary) form and a secondary form to other conditions are formally recognized. However, as several authors have suggested, it might be of clinical utility to consider the existence of a third clinical entity, namely Drug-Induced Burning mouth syndrome, for its therapeutic implications. The latter has been reported with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, antiretrovirals, anticoagulants, chemotherapy, and drugs commonly used in the treatment of neuropsychiatric disorders such as antidepressants, benzodiazepines, and antipsychotics. Regarding anticonvulsants a literature search found a previous case of Topiramate-Induced Burning mouth syndrome but no previous report of valproate-induced Burning mouth syndrome. Our case is, to date, the first case in the literature of Burning mouth syndrome onset following the administration of valproate to a patient suffering from fibromyalgia and bipolar spectrum disorder. Symptoms resolved completely when the drug was stopped, and the association between symptoms and drug was replicated after drug re-administration.</p>","PeriodicalId":72274,"journal":{"name":"Archive of clinical cases","volume":"10 3","pages":"125-127"},"PeriodicalIF":0.8000,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8e/85/acc-10-03-10257.PMC10510332.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archive of clinical cases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22551/2023.40.1003.10257","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Burning mouth syndrome is a chronic painful condition characterized by a subjective intraoral pain and burning sensations in the absence of an identifiable medical, dental, or psychiatric cause. Although the underlying etiology is currently unclear, an idiopathic (or primary) form and a secondary form to other conditions are formally recognized. However, as several authors have suggested, it might be of clinical utility to consider the existence of a third clinical entity, namely Drug-Induced Burning mouth syndrome, for its therapeutic implications. The latter has been reported with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, antiretrovirals, anticoagulants, chemotherapy, and drugs commonly used in the treatment of neuropsychiatric disorders such as antidepressants, benzodiazepines, and antipsychotics. Regarding anticonvulsants a literature search found a previous case of Topiramate-Induced Burning mouth syndrome but no previous report of valproate-induced Burning mouth syndrome. Our case is, to date, the first case in the literature of Burning mouth syndrome onset following the administration of valproate to a patient suffering from fibromyalgia and bipolar spectrum disorder. Symptoms resolved completely when the drug was stopped, and the association between symptoms and drug was replicated after drug re-administration.

丙戊酸钠诱导的男性纤维肌痛和双相情感障碍患者的灼口综合征。
灼口综合征是一种慢性疼痛疾病,其特征是在没有可识别的医学、牙科或精神原因的情况下,主观的口腔内疼痛和烧灼感。尽管潜在的病因目前尚不清楚,但特发性(或原发性)形式和其他疾病的继发形式已被正式承认。然而,正如几位作者所建议的那样,考虑第三种临床实体的存在,即药物诱导的灼口综合征的治疗意义,可能具有临床实用性。后者与血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂、抗逆转录病毒药物、抗凝剂、化疗以及常用于治疗神经精神疾病的药物如抗抑郁药、苯二氮卓类药物和抗精神病药物有关。关于抗惊厥药物,文献检索发现一例托吡酯诱导的灼口综合征,但没有丙戊酸钠诱导的灼嘴综合征的报告。到目前为止,我们的病例是文献中第一例在纤维肌痛和双相情感障碍患者服用丙戊酸钠后出现的灼口综合征。停药后症状完全缓解,重新给药后症状和药物之间的联系得以复制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信